Nicox submits Naproxcinod application with FDA
PARIS, Sept 25 |
PARIS, Sept 25 (Reuters) - French drug company Nicox (NCOX.PA) said on Friday it has submitted a new drug application for its anti-inflammatory drug Naproxcinod for osteoarthritis to the U.S. Food and Drug Administration (FDA).
The company said in a statement it plans to sumbit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in the fourth quarter of 2009.
(Reporting by Helen Massy-Beresford)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters